nipah
viru
niv
hendra
viru
hev
close
relat
deadli
zoonot
paramyxovirus
emerg
reemerg
last
year
studi
subunit
vaccin
formul
contain
recombin
solubl
attach
glycoprotein
hev
sg
hev
cpg
adjuv
evalu
potenti
niv
vaccin
cat
model
differ
amount
sg
hev
employ
sginduc
immun
examin
vaccin
anim
demonstr
vari
level
nivspecif
ig
system
importantli
vaccin
cat
possess
antigenspecif
iga
mucosa
upon
oronas
challeng
niv
tcid
vaccin
anim
protect
diseas
although
viru
detect
day
postchalleng
one
anim
abil
elicit
protect
system
mucos
immun
anim
model
provid
signific
progress
toward
develop
human
subunit
vaccin
henipavirus
hendra
viru
hev
nipah
viru
niv
close
relat
highli
pathogen
paramyxovirus
continu
caus
morbid
mortal
anim
human
fli
fox
genu
pteropu
consid
natur
reservoir
virus
geograph
distribut
encompass
locat
hev
niv
outbreak
occur
hev
appear
sporad
australia
sinc
infect
predominantli
hors
although
human
infect
also
occur
review
ref
two
report
fatal
human
case
one
present
sever
respiratori
diseas
succumb
enceph
recent
outbreak
hors
fatal
document
includ
one
human
case
report
first
niv
outbreak
occur
peninsular
malaysia
singapor
major
infect
pig
subsequ
transmiss
human
review
ref
human
develop
sever
febril
enceph
high
case
fatal
case
also
exhibit
respiratori
sign
niv
reemerg
repeatedli
sinc
twice
bangladesh
india
four
time
bangladesh
recent
india
bangladesh
recent
outbreak
includ
higher
incid
acut
respiratori
distress
syndrom
conjunct
enceph
epidemiolog
find
consist
persontoperson
transmiss
appar
higher
case
fatal
rate
furthermor
direct
transmiss
niv
fli
fox
human
suggest
niv
hev
distinguish
paramyxovirus
broad
speci
tropism
highli
pathogen
natur
classifi
new
genu
henipaviru
within
famili
paramyxovirida
classifi
zoonot
biosafeti
level
agent
virus
also
includ
among
pathogen
agent
biodefens
concern
center
diseas
control
prevent
cdc
nation
institut
allergi
infecti
diseas
niaid
mainli
due
access
environ
rel
eas
propag
dissemin
current
vaccin
avail
prevent
niv
hev
infect
agent
human
efficaci
studi
test
potenti
henipaviru
therapeut
product
easili
achiev
howev
henipaviru
anim
diseas
model
develop
review
ref
hev
niv
close
relat
develop
one
crossreact
vaccin
would
ideal
protect
infect
either
viru
paramyxovirus
larg
envelop
negativesens
ssrna
virus
entri
paramyxovirus
host
cell
twostep
process
mediat
attach
glycoprotein
bind
host
receptor
fusion
f
glycoprotein
drive
virushost
cell
membran
merger
hev
niv
attach
glycoprotein
g
lack
haemagglutinin
neuraminidas
activ
f
glycoprotein
typic
class
fusion
glycoprotein
review
ref
paramyxovirus
major
neutralis
antibodi
elicit
envelop
glycoprotein
infect
host
furthermor
neutralis
antibodi
key
vaccineinduc
protect
mechan
human
paramyxovirus
mump
mev
three
approach
emerg
henipaviru
vaccin
develop
incorpor
one
henipaviru
envelop
glycoprotein
review
ref
recombin
vaccinia
canarypox
virus
encod
either
niv
f
g
shown
protect
niv
challeng
golden
hamster
pig
respect
recombin
hev
niv
g
sg
hev
sg
niv
respect
use
subunit
vaccin
cat
niv
challeng
model
anim
protect
diseas
although
either
sg
hev
sg
niv
abl
protect
niv
sg
hev
elicit
highertitr
crossreact
henipaviru
immun
respons
recent
serolog
studi
also
suggest
crossreact
henipaviru
immun
respons
gener
upon
infect
hev
compar
niv
togeth
data
set
suggest
hevderiv
vaccin
would
protect
challeng
either
viru
describ
vaccin
challeng
trial
cat
use
new
sg
subunit
vaccin
formul
vari
dose
sg
hev
use
vaccin
immunogen
small
cpg
dna
molecul
use
adjuv
vaccin
anim
challeng
oronas
high
dose
low
passag
niv
isol
preand
postchalleng
immun
respons
examin
data
indic
new
subunit
vaccin
formul
induc
system
well
mucos
immun
viral
load
significantli
reduc
vaccin
anim
compar
adjuv
alon
control
anim
vaccin
anim
protect
nivmedi
diseas
eight
adult
month
old
domest
shorthair
cat
four
castrat
male
four
entir
femal
use
vaccin
efficaci
studi
anim
husbandri
method
experiment
design
endors
csiro
australian
anim
health
laboratori
anim
ethic
committe
anim
allow
free
roam
singl
room
vaccin
phase
studi
day
subsequ
reloc
individu
cage
singl
room
remaind
experi
individu
cage
size
environment
condit
previous
describ
anim
within
visual
auditori
contact
fed
twice
daili
complet
premium
dri
food
provid
water
ad
lib
room
fit
surveil
camera
allow
regular
monitor
anim
collect
specimen
cat
anaesthetis
previous
describ
tracheobronchi
wash
taken
cat
endotrach
tube
method
cat
sternal
recumb
head
held
follow
laryng
desensitis
anaesthet
spray
cophenylcain
fort
ent
technolog
melbourn
vic
australia
cat
intub
steril
dog
urinari
cathet
size
french
gentli
insert
endotrach
tube
far
would
go
via
attach
syring
ml
steril
phosphat
buffer
salin
pb
instil
cathet
immedi
aspir
usual
aspir
contain
floccul
mucu
procedur
deem
success
mucu
present
aspir
procedur
repeat
anesthet
revers
done
previous
describ
staff
wore
fulli
encapsul
suit
breath
apparatu
anim
room
laboratori
serum
neutralis
test
viru
isol
initi
stage
rna
extract
postchalleng
elisa
ig
cytokin
carri
product
purif
sg
hev
done
previous
describ
dose
allhydrogel
tm
sg
hev
mix
first
odn
ad
vaccin
dose
adjust
ml
pb
mixtur
incub
rotat
wheel
room
temperatur
least
h
prior
inject
eight
adult
cat
immunis
intramuscularli
vaccin
prepar
day
day
cat
receiv
ml
dose
prime
boost
inject
vaccin
dose
given
via
intramuscular
inject
two
anim
receiv
g
dose
cat
cat
two
anim
receiv
g
dose
cat
cat
two
anim
receiv
g
dose
cat
cat
two
anim
receiv
adjuvantalon
cat
cat
dose
group
contain
one
male
one
femal
cat
anim
bled
day
day
day
respiratori
wash
collect
day
day
describ
day
anesthesia
describ
singl
stage
transmitt
fit
intern
loop
antenna
coat
inert
twopot
epoxi
resin
sirtrack
havelock
north
new
zealand
implant
subcutan
flank
final
dimens
mm
mm
mm
realtim
monitor
bodi
temperatur
anim
use
singl
stage
transmitt
done
previous
describ
day
anim
inocul
oronas
tcid
low
passag
niv
isol
eukk
stock
viru
titr
tcid
ml
prepar
describ
previous
cat
assess
daili
score
rang
clinic
observ
includ
alert
groom
behavior
curios
depress
food
consumpt
faec
product
respir
rate
clinic
score
day
combin
provid
cumul
daili
score
rectal
temperatur
bodi
weight
record
sampl
period
occur
everi
second
day
cat
clinic
assess
exhibit
sign
diseas
anim
immobilis
describ
blood
collect
via
intracardiac
punctur
anim
immedi
euthanis
intraven
inject
sodium
pentabarbiton
heparinis
blood
oral
swab
urin
collect
day
postinfect
dpi
dpi
dpi
dpi
dpi
mucos
wash
collect
dpi
dpi
dpi
describ
immedi
follow
sampl
two
ml
aliquot
whole
blood
remov
blood
sampl
plasma
collect
aliquot
duplic
swab
immedi
place
ml
pb
ml
rnalat
ambion
inc
austin
usa
urin
collect
cat
manual
express
specimen
place
c
analysi
euthanasia
tissu
sampl
collect
asept
lung
apic
diaphragmat
lobe
brain
olfactori
occipit
lobe
heart
bronchial
lymph
node
spleen
liver
kidney
bladder
adren
gland
addit
femal
cat
uterin
horn
ovari
collect
male
cat
test
collect
tissu
either
fix
neutral
buffer
formalin
h
prior
histolog
process
submerg
ml
rnalat
pb
store
c
analysi
viru
neutralis
antibodi
titr
determin
previous
describ
briefli
plasma
sampl
dilut
eagl
minim
essenti
medium
emem
contain
fetal
calf
serum
fc
subject
doubl
dilut
start
prechalleng
postchalleng
fifti
microlitr
plasma
dilut
ad
well
quadrupl
plate
follow
l
viru
contain
tcid
either
hev
niv
incub
c
min
twenti
thousand
vero
cell
ad
well
l
incub
c
day
humidifi
co
incub
neutralis
titr
determin
dilut
cytopath
effect
cpe
observ
elisa
plate
coat
ng
either
sg
hev
sg
niv
incub
overnight
c
assay
sg
hev
sg
niv
antigen
batch
prepar
plate
wash
three
time
pbst
well
block
skim
milkpbst
h
c
transfer
laboratori
plasma
sampl
mucos
wash
dilut
ca
mg
free
pb
pbsa
assay
duplic
plasma
sampl
wash
ad
incub
h
c
plate
wash
three
time
pbst
subsequ
fix
icecold
absolut
methanol
least
min
prior
airdri
outsid
laboratori
plate
wash
three
time
pbst
horseradish
peroxidas
hrp
conjug
purchas
bethyl
inc
montgomeri
tx
usa
optim
work
dilut
determin
hrpgoat
antifelin
igg
hrpgoat
antifelin
igm
hrpgoat
antifelineiga
ad
incub
h
c
plate
wash
three
time
pbst
develop
tetramethylbenzidin
tmb
substrat
sigmaaldrich
st
loui
mo
usa
absorb
well
measur
nm
prechalleng
plasma
mucos
wash
test
laboratori
therefor
sampl
methanol
fixat
step
done
felin
cytokin
kit
relev
cytokin
elisa
reagent
purchas
r
system
inc
minneapoli
mn
usa
protocol
follow
per
manufactur
instruct
sever
variat
briefli
elisa
plate
coat
kit
suppli
captur
antibodi
goat
antifelin
ngwell
mous
antifelin
ngwell
mous
antifelin
ngwell
goat
antifelin
ngwell
incub
h
c
plate
wash
three
time
pbst
well
block
bsapbsa
h
c
transfer
laboratori
felin
cytokin
standard
plasma
sampl
mucos
wash
tissu
homogen
includ
lung
apic
diaphragmat
lobe
bronchial
lymph
node
spleen
prepar
describ
dilut
pbsa
assay
duplic
standard
concentr
rang
ngml
ngml
standard
concentr
rang
ngwell
ngml
cytokin
standard
plasma
sampl
mucos
wash
tissu
homogen
ad
incub
h
c
plate
wash
three
time
pbst
biotinyl
goat
anticanin
biotinyl
goat
antifelin
biotinyl
goat
antifelin
biotinyl
goat
antifelin
ad
incub
h
c
plate
wash
three
time
pbst
subsequ
fix
icecold
absolut
methanol
least
min
prior
airdri
outsid
laboratori
plate
wash
three
time
pbst
streptavidinhrp
ad
well
incub
h
c
plate
wash
three
time
pbst
develop
tmb
substrat
sigma
absorb
well
measur
nm
prechalleng
plasma
sampl
mucos
wash
test
laboratori
therefor
sampl
correspond
standard
curv
methanol
fixat
step
done
rna
isol
blood
cell
use
ribopureblood
kit
ambion
inc
swab
urin
use
qiaamp
viral
rna
kit
qiagen
pti
ltd
clifton
hill
australia
tissu
use
rneasi
mini
kit
qiagen
pti
ltd
briefli
condit
l
blood
ad
l
ribopur
lysi
buffer
l
sodium
acet
one
hundr
forti
microlitr
swab
solut
urin
ad
l
avl
viral
lysi
buffer
qiaamp
tissu
homogenis
remov
tissu
rnalat
ad
tube
contain
l
rlt
lysi
rneasi
contain
l
l
volum
mm
zirconiasilica
bead
biospec
product
inc
bartlesvil
usa
sampl
homogenis
cycl
use
minibead
beater
biospec
product
inc
centrifug
pellet
cell
debri
supernat
transfer
new
tube
sampl
remov
lab
process
accord
manufactur
instruct
suppli
kit
taqman
pcr
assay
preform
previous
describ
sampl
amplifi
geneamp
sequenc
detect
system
appli
biosystem
foster
citi
ca
usa
standard
curv
obtain
niv
specif
cdna
triplic
assay
threshold
cycl
ct
valu
obtain
standard
dilut
plot
input
cdna
concentr
creat
standard
curv
data
shown
linear
regress
analysi
use
quantifi
niv
cdna
ct
valu
repres
niv
genom
sampl
analys
rel
standard
niv
cdna
dilut
pg
niv
cdna
data
shown
rel
niv
genom
level
viru
isol
done
previous
describ
viru
isol
attempt
specimen
posit
niv
genom
tissu
process
routin
histolog
method
section
tissu
stain
hematoxylin
eosin
examin
histopatholog
chang
separ
section
stain
immunohistochem
techniqu
previous
describ
use
rabbit
polyclon
antiserum
recombin
niv
nucleoprotein
previou
niv
vaccin
trial
three
high
dose
sg
hev
sg
niv
immunis
administ
cat
along
potent
adjuv
yield
except
high
neutralis
antibodi
titr
challeng
carri
tcid
dose
niv
inject
subcutan
anim
surviv
viru
recov
time
point
postchalleng
suggest
sterilis
immun
sought
better
assess
sgspecif
immun
respons
thu
new
vaccin
trial
devis
employ
vari
dose
sg
hev
addit
hev
niv
replic
caus
sever
patholog
lung
cpg
adjuv
includ
attempt
elicit
mucos
immun
eight
adult
cat
immunis
describ
method
schemat
diagram
outlin
vaccin
specimen
collect
niv
challeng
shown
fig
anim
receiv
one
prime
one
boost
intramuscularli
period
anim
bled
plasma
antibodi
respons
specif
either
sg
hev
sg
niv
measur
result
shown
fig
expect
cat
regardless
ig
subclass
sg
hev
specif
antibodi
level
slightli
higher
specif
sg
niv
cat
signific
level
igg
day
increas
upon
boost
day
appear
notabl
differ
among
differ
vaccin
dose
plasma
igm
level
vari
although
cat
demonstr
sg
hev
specif
igm
cat
g
dose
cat
cat
g
dose
cat
demonstr
increas
level
sg
niv
specif
igm
unlik
igg
respons
igm
level
appear
decreas
upon
boost
signific
level
plasma
iga
detect
cat
level
decreas
upon
boost
wherea
cat
g
dose
cat
appear
slight
increas
iga
upon
boost
plasma
sampl
evalu
niv
serum
neutralis
test
snt
result
shown
tabl
anim
low
level
neutralis
antibodi
day
prime
cat
g
dose
cat
like
two
adjuvantonli
control
cat
cat
neg
upon
boost
snt
titr
increas
anim
larg
differ
titr
observ
cat
vaccin
g
although
male
cat
slightli
higher
titr
femal
snt
titr
lower
anim
receiv
g
sg
hev
cat
demonstr
higher
snt
titr
hev
anim
receiv
g
sg
hev
exhibit
lowest
snt
titr
data
shown
determin
vaccin
target
mucos
surfac
tracheobronchi
wash
collect
sg
hev
specif
secretori
iga
measur
result
shown
fig
cat
increas
level
mucos
iga
compar
day
cat
cat
g
dose
cat
cat
lower
secretori
iga
level
demonstr
higher
vaccin
dose
gener
highest
mucos
antibodi
respons
addit
three
anim
two
femal
cat
lowest
amount
mucos
iga
igm
detect
mucos
wash
fig
examin
extent
sg
hev
induc
immun
abil
protect
lethal
niv
challeng
high
dose
viru
tcid
employ
oronas
challeng
use
mimic
natur
rout
infect
day
postinfect
dpi
two
control
anim
cat
develop
acut
febril
diseas
c
compar
seen
previous
experiment
infect
cat
given
tcid
niv
oral
intranas
rise
temperatur
observ
anim
preced
increas
respiratori
rate
approxim
h
data
shown
expect
base
prior
studi
rise
cumul
daili
clinic
score
observ
parallel
increas
respiratori
rate
data
shown
welfar
reason
cat
allow
progress
seriou
clinic
diseas
control
anim
euthanis
dpi
necropsi
examin
grossli
visibl
chang
discret
redden
lesion
margin
lung
tissu
one
control
anim
cat
microscop
examin
control
anim
multipl
foci
necrotis
alveol
lung
parenchyma
cat
advanc
lesion
margin
lung
consist
alveolar
necrosi
interstiti
inflammatori
infiltr
predominantli
neutrophil
necrotis
bronchiol
affect
bronchiol
alveolar
epithelium
consist
swollen
cell
fuse
multinucl
cell
syncytia
affect
epitheli
cell
frequent
eosinophil
intracytoplasm
inclus
bodi
fig
bronchial
lymph
node
cat
subcapsular
focal
necrosi
small
number
syncytia
spleen
multipl
foci
necrosi
affect
red
pulp
splenic
nodul
intranuclear
intracytoplasm
antigen
stain
present
affect
bronchiol
alveolar
epithelium
control
cat
fig
within
lymph
node
lesion
convers
vaccin
cat
demonstr
clinic
sign
nivmedi
diseas
surviv
euthanasia
dpi
bodi
temperatur
rose
gradual
cat
cours
infect
howev
clinic
sign
diseas
present
upon
postmortem
examin
signific
lesion
viral
antigen
detect
six
vaccin
cat
data
shown
plasma
ig
level
measur
use
sgspecif
elisa
anim
postchalleng
chang
titr
note
data
shown
except
plasma
iga
igm
two
low
dose
anim
fig
dpi
cat
increas
igm
dpi
igm
level
return
prechalleng
level
fig
cat
iga
level
decreas
follow
niv
challeng
howev
dpi
sg
hev
sg
niv
specif
iga
increas
level
remain
elev
euthanasia
fig
cat
igm
level
increas
dpi
elev
dpi
return
prechalleng
level
dpi
fig
cat
increas
level
iga
dpi
decreas
prechalleng
level
dpi
slight
increas
also
note
dpi
particularli
sg
niv
specif
iga
fig
plasma
sampl
anim
also
evalu
use
snt
result
shown
tabl
control
cat
low
snt
titr
dpi
wherea
control
cat
remain
snt
neg
vaccin
cat
snt
titr
decreas
day
compar
day
cat
cat
g
dose
cat
snt
titr
chang
slightli
cours
infect
cat
fourfold
increas
snt
titr
dpi
cat
eightfold
increas
titr
dpi
togeth
data
demonstr
ele
vate
immun
respons
follow
niv
challeng
cat
snt
titr
remain
rel
stabl
increas
significantli
dpi
dpi
larg
increas
titr
like
repres
increas
immun
respons
replic
niv
determin
mucos
ig
level
chang
postchalleng
tracheobronchi
wash
collect
dpi
dpi
dpi
evalu
sgspecif
iga
igm
seen
prechalleng
igm
detect
mucos
wash
data
shown
convers
measur
iga
detect
anim
postchalleng
result
shown
fig
cat
signific
amount
iga
dpi
wherea
iga
level
low
vaccin
anim
comparison
dpi
mucos
iga
level
increas
vaccin
anim
except
cat
high
level
prechalleng
mucos
iga
two
femal
anim
cat
least
amount
mucos
iga
prechalleng
signific
increas
postchalleng
demonstr
increas
immun
respons
niv
challeng
dpi
mucos
iga
almost
undetect
plasma
mucos
tissuespecif
level
measur
use
felinespecif
cytokin
elisa
describ
method
cytokin
detect
preor
postchalleng
sampl
seven
eight
anim
includ
two
control
cat
contrast
cytokin
detect
plasma
cat
data
shown
cat
signific
level
detect
level
day
day
day
cytokin
still
detect
decreas
significantli
upon
niv
challeng
cytokin
increas
highest
elev
ascertain
niv
tropism
shed
postchalleng
blood
oral
swab
urin
tissu
collect
cat
sampl
initi
screen
use
quantit
taqman
pcr
assay
target
niv
rna
nucleoprotein
gene
code
region
previou
studi
cat
demonstr
detect
niv
genom
taqman
pcr
particularli
blood
oral
swab
urin
sensit
assay
viru
isol
present
studi
niv
genom
detect
blood
sampl
anim
time
point
data
shown
niv
genom
detect
oral
swab
cat
postchalleng
result
shown
fig
highest
level
appar
shed
occur
dpi
dpi
cat
appear
shed
viru
low
level
dpi
consist
postchalleng
snt
data
suggest
increas
immun
respons
replic
viru
anim
viru
isol
attempt
niv
genom
posit
oral
swab
unfortun
cell
toxic
sampl
preclud
success
isol
urin
sampl
collect
opportunist
cat
postchalleng
assay
use
taqman
pcr
result
shown
fig
similar
swab
data
highest
level
appar
shed
urin
occur
dpi
dpi
viru
isol
attempt
urin
sampl
neg
variabl
success
isol
niv
urin
sampl
infect
cat
report
although
base
taqman
pcr
viru
isol
data
suggest
cat
shed
signific
amount
niv
follow
challeng
data
dpi
dpi
may
repres
clearanc
initi
inoculum
replic
viru
howev
detect
niv
genom
urin
swab
low
dose
cat
dpi
perhap
stronger
indic
replic
viru
anim
despit
failur
viru
isol
tissu
collect
upon
euthanasia
also
assay
viral
rna
result
shown
fig
similar
previou
studi
niv
infect
cat
control
cat
signific
amount
niv
genom
wide
rang
tissu
highest
level
present
lung
spleen
fig
viru
isol
conduct
tissu
posit
presenc
niv
genom
howev
viru
isol
lung
spleen
major
tissu
assay
vaccin
cat
day
neg
niv
genom
howev
signific
level
genom
detect
brain
fig
unexpectedli
cat
demonstr
highest
level
genom
brain
tissu
level
significantli
higher
seen
control
cat
viru
isol
confirm
presenc
niv
cat
brainolfactori
wherea
cat
viru
isol
viral
antigen
detect
brain
immunohistochemistri
clearli
vaccin
anim
system
nivmedi
diseas
multipl
organ
system
patholog
reduc
almost
entir
except
niv
genom
detect
brain
sever
anim
signific
data
remain
elucid
present
activ
passiv
therapeut
procedur
prevent
treat
niv
hev
infect
result
natur
outbreak
laboratori
accid
deliber
misus
conduct
second
sghenipaviru
vaccin
trial
cat
progress
human
henipaviru
vaccin
candid
persontoperson
transmiss
niv
occur
recent
outbreak
vaccin
may
prove
use
futur
outbreak
decreas
transmiss
addit
henipaviru
vaccin
would
benefici
laboratori
staff
first
respond
may
encount
deliber
misus
either
viru
hev
niv
pathogen
human
efficaci
studi
permit
vaccin
develop
howev
us
food
drug
administr
fda
implement
anim
efficaci
rule
evalu
therapeut
product
circumst
specif
fda
reli
evid
deriv
anim
studi
evalu
product
effect
howev
wellunderstood
mechan
pathogen
agent
conjunct
underli
mechan
action
product
must
document
previou
studi
document
mechan
pathogen
agent
demonstr
protect
niv
challeng
cat
use
recombin
sg
subunit
vaccin
studi
suggest
vaccin
anim
develop
sterilis
immun
complet
second
sg
vaccin
trial
aim
influenc
understand
detail
manner
mechan
sginduc
immun
cpg
motif
adjuv
employ
previous
human
known
stimul
mucos
immun
util
vari
dose
sg
minimum
immunis
regimen
one
prime
one
boost
employ
goal
elicit
rang
humor
immun
respons
final
unlik
previou
sg
vaccin
trial
tcid
employ
subcutan
studi
high
niv
challeng
dose
employ
administ
oronas
rout
challeng
close
mimick
natur
infect
upon
vaccin
antigenspecif
plasma
ig
gener
anim
igg
abund
subclass
igm
iga
level
vari
accord
vaccin
dose
suggest
subtl
differ
potenc
immun
respons
vaccin
anim
signific
percentag
antigenspecif
ig
neutralis
capabl
demonstr
snt
titr
mucos
iga
detect
vaccin
anim
suggest
cpg
adjuv
help
target
immun
respons
mucosa
howev
iga
level
correl
vaccin
dose
absolut
level
plasma
ig
vari
greatli
postchalleng
snt
titr
increas
three
lowest
dose
cat
suggest
viru
replic
occur
observ
differ
increas
snt
titr
postchalleng
rel
unchang
level
sgspecif
plasma
ig
might
repres
antibodi
respons
direct
viral
protein
besid
attach
glycoprotein
equal
possibl
although
sgspecif
antibodi
increas
increas
sgspecif
antibodi
affin
could
led
increas
potenc
snt
combin
sg
hev
cpg
induc
suffici
level
antigenspecif
plasma
ig
neutralis
antibodi
antigenspecif
mucos
iga
protect
cat
lethal
niv
challeng
four
six
vaccin
anim
evid
viral
replic
evid
whether
indic
increas
snt
titr
mucos
iga
immun
respons
elicit
vaccin
suffici
protect
anim
system
nivmedi
diseas
unexpect
find
cytokin
examin
studi
undetect
anim
includ
adjuvantalon
control
thorough
plasma
mucos
wash
tissu
homogen
lung
spleen
bronchial
lymph
node
test
unlik
highli
pathogen
human
viral
respiratori
pathogen
sever
acut
respiratori
syndrom
sar
rsv
highli
pathogen
influenza
viru
cytokin
storm
appear
play
role
earli
stage
nivmedi
diseas
futur
studi
aim
understand
function
tcell
critic
determin
role
cytokin
protect
diseas
indirectli
measur
effect
vaccineinduc
immun
assess
viral
shed
viral
load
nivassoci
patholog
cat
postchalleng
prolong
appar
viral
shed
demonstr
oral
swab
three
vaccin
cat
vaccin
anim
system
nivmedi
diseas
practic
negat
evidenc
lack
clinic
diseas
gross
microscop
patholog
absenc
immunohistochem
antigen
stain
minim
detect
niv
genom
variou
tissu
surprisingli
although
viral
antigen
detect
brain
tissu
vaccin
anim
rel
high
amount
niv
genom
detect
brain
four
higher
vaccin
dose
cat
niv
isol
one
brain
tissu
confirm
presenc
infecti
viru
two
low
vaccin
dose
anim
lowest
prechalleng
snt
titr
level
niv
genom
brain
either
undetect
bare
threshold
assay
notabl
vaccin
cat
demonstr
niv
genom
brain
signific
antibodi
titr
prior
challeng
observ
indic
persist
infect
niv
cat
may
occur
despit
presenc
preexist
immun
persist
infect
may
even
enhanc
particular
level
immun
mechan
effect
unclear
requir
investig
due
constraint
work
small
number
cat
use
would
use
strengthen
statist
signific
find
repeat
similar
trial
therebi
increas
number
infect
anim
data
suggest
although
protect
diseas
achiev
current
vaccin
studi
antigen
dose
use
suffici
prevent
viru
infect
brain
remain
unknown
whether
niv
detect
within
brain
anim
would
eventu
clear
host
neurolog
diseas
would
manifest
later
date
howev
consid
significantli
longer
period
recurr
diseas
document
occur
human
rang
sever
month
nearli
year
longterm
studi
nearli
imposs
conduct
contain
summari
achiev
protect
cat
lethal
niv
challeng
use
recombin
sg
hev
subunit
vaccin
conjunct
cpg
adjuv
importantli
data
suggest
one
vaccin
could
develop
henipavirus
furthermor
better
understand
mechan
sginduc
immun
niv
infect
elucid
provid
import
inform
requir
fda
human
vaccin
candid
vaccin
dose
employ
reveal
subtl
differ
immun
respons
protect
diseas
highlight
import
consider
futur
sg
vaccin
trial
